Oncologists already know that brachytherapy radiation is a highly effective treatment for some cancers. Initially Oncosil will be a last resort treatment that can be offered in place of external radiation, that should reduce pain and extend life, avoiding the more damaging effect of external radiation. It can be offered as an alternative to the patient, clearly on a user pay basis initially. The CE marking clearly allows and requires post marketing clinical data to be submitted. Interest in the technique will be high. Once CE is granted big Pharma will be watching very closely. Even at double the current market cap it would be a very cheap buy to get this product with growth potential. The take over offer is out there, CE should bring it on.
OSL Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)